Accelrys has announced that it has acquired privately-held VelQuest, a provider of paperless lab execution systems supporting current Good Manufacturing Practices (cGMP) for FDA-regulated industries including pharmaceuticals and biotechnology organisations. The acquisition of VelQuest has extended Accelrys' software portfolio into the downstream pharmaceutical development Quality Assurance and Quality Control (QA/QC) space, offering productivity improvements, faster cycle times, lower operational costs and reduced compliance risks for regulated life sciences organisations.
All key members of the VelQuest management team have been retained and VelQuest's Ken Rapp, along with his team, will continue to lead Accelrys' efforts in paperless analytical and quality operations for life sciences. In addition to complementing Accelrys Pipeline Pilot and Symyx Notebook by Accelrys, the VelQuest systems significantly reduce the resources needed for paperless analytical and quality operations, including analyst data acquisition and documentation, data review, supervisor approval, QA investigations, audits and releases. Some integration has already taken place between the VelQuest offerings and existing Accelrys solutions, opening the door to further synergies and downstream opportunities as a result of this acquisition.
